Review of 2009: Buy, sell and grow – an eventful year for Covidien
This article was originally published in Clinica
Executive Summary
In 2009, no medtech firm was more active in the M&A market than Covidien. Along with a relocation to Ireland and having to face the challenges of an ongoing imaging isotope shortage, it has been a busy year for the firm. Joseph Harvey spoke with chairman, president and CEO Richard Meelia about where 2009 has left Covidien in the medtech hierarchy